Release Date: July 30, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Second quarter organic revenue growth of 5% exceeded expectations, driven by broad-based operational performance across all segments and divisions.
- Strong double-digit growth in drug compounding and continued robust performance in advanced surgery (12% growth) highlight key growth drivers.
- Positive free cash flow generation of $181 million in Q2 and $257 million year-to-date, reflecting improved working capital and strengthening financial flexibility.
- Progress on the Baxter GPS continuous improvement program, with over 400 events completed and hundreds more planned, driving efficiency and execution.
- Innovation momentum with new product launches like PeerView, Vest APX Acute Care, and Dynamo smart stretcher, expanding market offerings and customer value.
Negative Points
- Adjusted EPS declined 5% year-over-year to $0.56, impacted by higher manufacturing costs and unfavorable prior-year cost comparisons.
- Novum IQ LVP infusion pump remains under shipment and installation hold due to field actions, with ongoing regulatory engagement and no timeline for resolution.
- Supply constraints persist in injectables and certain premixed products, particularly from a contract manufacturer, pressuring pharmaceutical portfolio performance.
- Gross margin decreased 210 basis points to 38.6%, driven by higher cost inventory roll-through and tariff impacts, partially offset by a one-time tariff refund.
- Full-year organic sales growth guidance raised to only 2%-3%, reflecting cautious outlook amid macroeconomic uncertainty and potential hospital capital spending slowdown.
Q & A Highlights
Here are the key highlights from Baxter International Inc.'s Q2 2026 earnings call, presented as Q&A pairs.Q: Can you unpack the drivers of the strong Q2 top-line beat and the confidence behind the guidance raise? Also, given the one-time tariff refund, does the lower implied second-half EPS guidance suggest caution, and are you still confident in EPS growth for 2027?
A: (Andrew Hider, President and CEO) The Q2 beat was driven by broad-based operational performance across all segments and divisions, including double-digit growth in drug compounding, strong performance in advanced surgery, and solid demand in IV solutions and patient support systems. The tariff refund of $0.11 per share was not contemplated in original guidance. While we are pleased with the quarter, it is just one quarter, and we are focused on executing in the second half of 2026. The non-recurring tariff benefit will not flow through to 2027, and we will provide more color on 2027 at the appropriate time.
Q: What is the status of the Novum IQ LVP pump, and what are the next steps? If it doesn't return to market, how durable is the Spectrum IQ pump as a workhorse?
A: (Andrew Hider, President and CEO) We are making progress on the Novum IQ LVP. We have identified corrections and are in the early stages of verification testing. We continue to work closely with regulatory authorities and support current customers with available mitigations. We like our total pump portfolio, which includes the Novum syringe and Spectrum LVP on the IQX platform, and we recently launched PeerView to enhance our digital roadmap. We are focused on bringing value to customers today and will launch Novum LVP when it is ready.
Q: How large was the drug compounding business in Q2, and did its lower margin profile contribute to the gross margin being a bit light?
A: (Kevin Moran, VP of Investor Relations) Drug compounding was a good chunk of the beat in Q2 and grew double-digits. It inherently has a lower margin, which does impact the mix. (Andrew Hider, President and CEO) While pleased with the growth, this business has favorable cash conversion, and we are focused on driving margin improvement.
Q: The Q2 beat included a $0.11 tariff refund, higher TSA income, and lower interest. Why is the full-year EPS guidance only raised by $0.10? Is this conservatism for the second half?
A: (Kevin Moran, VP of Investor Relations) The higher TSA income in Q2 was offset by higher TSA-related expenses, so it was not material to operating income. The full-year EPS guidance raise primarily reflects the one-time tariff refund. The underlying operating performance framework for the second half remains consistent with our previous expectations, including higher volumes, cost structure benefits, and the roll-through of higher-cost inventory.
Q: Can you talk about the order book and any signs of a slowdown in hospital capital spending, particularly for the Connected Care business?
A: (Andrew Hider, President and CEO) Demand remains stable, supported by a strong US capital order book and funnel visibility across Patient Support Systems and Global Supply Systems. We are staying close to the market and have not observed any change in hospital capital spending behavior. Customer feedback on new products like the Dynamo stretcher is positive, but we are not immune to broader macroeconomic uncertainty and continue to monitor the environment closely.
Q: What is the plan to turn around the injectables and anesthesia business, which remains pressured?
A: (Andrew Hider, President and CEO) The business remains pressured due to ongoing supply constraints, particularly from a contract manufacturer. We are taking specific actions to improve supply conditions on select products and are working closely with the contract manufacturer to improve operational efficiency and quality. The full-year guidance has this built in.
Q: Was there any restocking benefit from IV Fluids in Q2, given the market rebasing?
A: (Andrew Hider, President and CEO) We did not see a massive restocking in IV Solutions, so it was not material. We are operating at the new norm baseline and feel good about our market position and the value we bring to customers.
Q: The organic revenue guidance was raised, but the implied EPS for the second half seems lighter. What are the good guys and bad guys on margins for the rest of the year?
A: (Kevin Moran, VP of Investor Relations) The operating margin framework remains consistent: first-half headwinds followed by second-half improvement. The new item is the non-recurring Q2 tariff refund. For the balance of the year, you should normalize for that and then expect sequential improvement from higher volumes, cost structure actions, and the roll-through of higher-cost inventory, which will be a Q2 to Q3 sequential improvement. (Andrew Hider, President and CEO) Supply chain pressures and oil prices are being managed and are within our guidance.
Q: Can you quantify the impact of planned product exits on Frontline Care's 2% growth in Q2, and what is the long-term growth aspiration for this business?
A: (Kevin Moran, VP of Investor Relations) The planned product exits were not material. Connect 360 did contribute to the growth. (Andrew Hider, President and CEO) We are focused on strong portfolio management and aligning with areas where we have value creation for customers. This includes launching new products and sustaining our solution set. It is early days, but the leadership team is focused on execution and value creation.
Q: Where has the turnaround gone better and faster than expected, and where has it been slower? How are you evolving your focus?
A: (Andrew Hider, President and CEO) I am very pleased with how the Baxter GPS (Growth and Performance System) has taken hold across the organization. We have completed over 400 continuous improvement events year-to-date, with many more in the pipeline. This is the driving force for consistent execution. There is no single innovation that will define our future; it is the accumulation of all these small improvements. I am never satisfied, but I am pleased with the progress. One quarter is one quarter, and we are focused on finishing the year strong and preparing for 2027.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
